Blood Pressure Treatment
- From: "Kara" <alabamalyme@xxxxxxx>
- Date: 11 Aug 2006 07:24:25 -0700
Medscape review supports effectiveness and safety of new non-drug blood
pressure treatment
Peer-Reviewed article highlights seven clinical trials of device-guided
breathing with RESPeRATE
Fort Lee, N.J. -- August 10, 2006--InterCure, Ltd., today announced the
publication of a peer-reviewed clinical overview of seven clinical
trials evaluating the efficacy of device-guided breathing. The study's
authors conclude that RESPeRATE, an FDA-cleared over-the-counter
therapeutic device, is an effective non-pharmacologic treatment option
for treating hypertension with no side effects.
The article, published in the General Medicine Journal
(http://www.medscape.com/viewarticle/539099) of Medscape (NASDAQ:WBMD),
is authored by William J. Elliott, MD, PhD, professor of Preventive
Medicine, Internal Medicine and Pharmacology at Rush Medical College,
Ill., and Joseph L. Izzo, Jr., MD, professor of medicine and vice chair
of Medical Research at the University of Buffalo, N.Y.
The article confirms the body of evidence from seven published clinical
studies concluding that routine use of RESPeRATE, either alone or as an
adjunctive treatment with lifestyle modifications or prescription
drugs, significantly lowered blood pressure with no adverse side
effects. The study also reviews the physiological mechanism of action
of device-guided breathing.
A summary of the results of the seven studies shows an average all-day
reduction of 14/8 mm Hg within four to six weeks of commencement of
15-minute-daily treatments with RESPeRATE. The reduction in blood
pressure was consistent between studies, whether measurements were
taken in the home, 24-hour ambulatory setting or physician's office.
Larger blood pressure reductions were seen in older individuals and
those with higher baseline readings, regardless of whether they were
also being treated with prescription antihypertensive medications.
The authors summarize the patient populations for whom device-guided
breathing appears to be beneficial: (1) prehypertensives and white-coat
or labile hypertensives who might benefit from reducing stress and
sympathetic activity; (2) patients with isolated systolic hypertension;
and (3) patients with resistant hypertension (uncontrolled blood
pressure despite use of a diuretic and at least two other medications
at maximum approved doses).
"When I was first introduced to RESPeRATE, I was skeptical, but after
seven trials, the body of data speaks for itself. I have seen
first-hand that as long as patients use the device regularly, blood
pressure is reduced, with no side effects," says Dr. William Elliott,
Rush Medical Center. "Controlling hypertension requires a comprehensive
approach, and device-guided breathing provides an additional effective
therapeutic modality to offer our patients."
More than 65 million Americans have high blood pressure, and even with
traditional treatment methods of diet, exercise and medication, 70
percent of that population is either unable to reach their lower blood
pressure goals or can't tolerate the side effects of medications. Left
untreated, high blood pressure may lead to heart attack, stroke and
kidney or heart failure.
###
About RESPeRATE
RESPeRATE® is FDA-cleared for over-the-counter sale and is the only
medical device on the market clinically proven to lower blood pressure
through paced breathing therapy. The device uses the body's natural
tendency to follow external rhythms, interactively guiding the user to
effortlessly reduce breathing rate to a "therapeutic zone" of less than
10 breaths per minute. The breathing exercises with RESPeRATE relax the
constricted muscles surrounding the small blood vessels, allowing the
blood to flow more freely and yielding a significant and lasting
reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, has become a leader in the growing
Personal Therapeutic Device category. Its broadly patented
"device-guided breathing" technology platform enables a systematic
reduction in sympathetic outflow of the autonomous nervous system.
InterCure is successfully selling the world's 1st hypertension
treatment device, RESPeRATE. With multiple published clinical
trials, regulatory approvals in most key markets (FDA over-the-counter
("OTC") clearance, CE mark, Chinese SDA, and others) and a renowned
scientific advisory board, RESPeRATE is rapidly becoming a part of the
standard of care for the treatment of hypertension. (www.intercure.com,
www.resperate.com)
.
- Prev by Date: AMERICA IN DANGER: Secret Torture Rooms
- Next by Date: Re: Pantethine?
- Previous by thread: AMERICA IN DANGER: Secret Torture Rooms
- Next by thread: tambocor and exercise
- Index(es):
Relevant Pages
|
